Journal
BIOMATERIALS
Volume 33, Issue 15, Pages 3931-3941Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.02.019
Keywords
Docetaxel; Carboxymethylcellulose; Conjugated Polymers; Magnetic nanoparticles
Funding
- Ontario Institute for Cancer Research, MaRS Innovation
- Ontario Centres of Excellence
- Canadian Institutes of Health Research
Ask authors/readers for more resources
A carboxymethylcellulose-based polymer conjugate with nanoparticle forming properties (Cellax) has been shown to enhance the pharmacokinetics, specificity of biodistribution, anti-tumor efficacy and safety of docetaxel (DTX) in comparison to the Taxotere (TM) formulation. We examined Cellax and Taxotere efficacy in four tumor models (EMT-6, B16F10, PD, and MDA-MB-231), and observed variances in efficacy. To explore whether differences in tumor uptake of Cellax were responsible for these effects, we incorporated superparamagnetic iron oxide nanoparticles (SPIONs) into Cellax particles to enable magnetic resonance (MR) imaging (Cellax-MR). In the EMT-6 tumor model, Cellax-MR nanoparticles exhibited peak tumor accumulation 3-24 h post intravenous injection, and 3 days post-treatment, significant MR contrast was still detected. The amount of Cellax-MR deposited in the EMT-6 tumors was quantifiable as a hypointense volume fraction, a value positively correlated with drug content as determined by LC/MS analysis (R-2 = 0.97). In the four tumor models, Cellax-MR uptake was linearly associated with anti-tumor efficacy (R-2 > 0.9), and was correlated with blood vessel density (R-2 > 0.9). We have affirmed that nanoparticle uptake is variable in tumor physiology, and that this efficacy-predictive parameter can be non-invasively estimated in real-time using a theranostic variant of Cellax. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available